Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...
Although Keytruda/Inlyta had a higher rate of adverse ... The novel treatment options involves patients attending bi-weekly for an IV infusion, allowing healthcare professionals to monitor ...
Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...
TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans ... and Encouraging Safety Profile in Combination with KEYTRUDA® ...
TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans ... and Encouraging Safety Profile in Combination with KEYTRUDA® ...
Pietro’s Trattoria broke ground for their new restaurant in Reynolds Ranch a couple weeks ago, according to owner Pete ...
Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...
Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...
Get detailed information on Pembrolizumab, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback